Navigation Links
Prostate cancer study proves drug delays disease progression
Date:1/23/2012

(TORONTO, Canada Jan. 24, 2012) For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride ("Avodart") delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network (UHN).

The findings are published online today in The Lancet. "The results prove that using active surveillance plus dutasteride is a viable, safe and effective treatment option for men who often undergo aggressive local treatment despite low risk of dying from the disease," says Dr. Fleshner, a surgical oncologist in UHN's Princess Margaret Cancer Program and Professor of Surgery at the University of Toronto. Dr. Fleshner also holds the Love Chair in Prostate Cancer Prevention Research.

"This is very good news for men with low-risk disease because aggressive treatment can have a major impact on their quality of life, with risks of impotence and incontinence," says Dr. Fleshner.

The three-year clinical trial enrolled 302 men between the ages of 48 and 82 diagnosed with low-risk localized prostate cancer and regularly monitored for clinical changes a treatment option called "active surveillance". In the trial known as REDEEM (REduction by Dutasteride of clinical progression Events in Expectant Management of prostate cancer) participants were randomized 1:1 to receive dutasteride or a matching placebo daily. The men also underwent biopsies at 1.5 and three years.

The study showed a significant delay in disease progression in the men treated with dutasteride 36% compared with 23% who received the placebo. As well, the final biopsies showed the men treated with the drug were less likely to have cancer detected 36% compared with 31%.

"This is the first study to show that a 5a-reductase inhibitor such as dutasteride reduces the need for aggressive treatment in low-risk disease," says Dr. Fleshner. "The drug, currently commonly used to treat enlarged prostate, works by inhibiting the male sex hormone that causes the enlargement in the first place."

Dr. Fleshner says a small percentage of men reported drug-related side effects including sexual difficulty with either desire or erections (5%), or breast tenderness or enlargement (3%). "It's important to realize that these drugs have been around for almost 20 years in clinical practice to treat enlarged prostates and so we have a wealth of knowledge about their side effects, which are reversible if the drug is stopped."

Participants were also assessed for cancer-related anxiety and the men on dutasteride reported feeling much less anxious because their biopsies and PSA values improved, adds Dr. Fleshner. (PSA or prostate-specific antigen is a blood test used to help diagnose prostate cancer.)

The Canadian Cancer Society estimates 25,500 new cases of prostate cancer will be diagnosed this year and that 4,100 men will die from the disease.


'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.ca
416-946-2846
University Health Network
Source:Eurekalert

Related medicine news :

1. Eating smart: Researcher studies foods, dietary supplements that may reduce risk of prostate cancer
2. Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival
3. Music May Ease Anxiety, Pain in Prostate Biopsy Patients
4. UNC scientists collaborate to find first major genetic mutation associated with hereditary prostate cancer risk
5. Scientists Identify Inherited Prostate Cancer Gene
6. Headphone music eases anxiety during prostate biopsies
7. PSA Test for Prostate Cancer Doesnt Save Lives: Study
8. Mass prostate cancer screening doesnt reduce deaths
9. Proton therapy effective prostate cancer treatment
10. PSA testing, combined with other relevant patient data can reduce unnecessary prostate biopsies
11. Panel endorses active monitoring and delay of treatment for low-risk prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located in ... and leads programs. , In February, 2017, Empower Brokerage introduced their new “Performance ... is designed to teach how to maximize their sales efforts, as well as ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... collection of inspiring stories about real people of God in congregations across the ... John Miller, a Presbyterian minister ordained in 1964 who has served congregations in ...
(Date:3/23/2017)... ... 23, 2017 , ... Demonstrating their commitment to improving health ... departments have been awarded national accreditation through the Public Health Accreditation Board ... network of communities across the nation whose health departments meet rigorous national standards ...
(Date:3/23/2017)... ... ... 82% of adults are unaware of the dangers that infectious bacteria play in mouth disease, ... times a day that dentists recommend. The ramifications of improper oral upkeep go far beyond ... missing 164 million hours of work each year due to dental issues. That is why ...
(Date:3/23/2017)... CA (PRWEB) , ... March 23, 2017 , ... ... funding investment in Los Angeles based healthcare technology company California Healthcom Group (CHG). ... into the US, and healthcare arena. With headquarters in California, CHG is a ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017  Transportation Insight, a multi-modal ... end-to-end supply chain management firm with expertise serving clients ... Solutions Rick Zaffarano was named a 2017 ... Supply Chain by the only publication exclusively dedicated to ... supply chain. "Rick has brought to Transportation ...
(Date:3/23/2017)... March 23, 2017 ... Healthcare disease pipeline guide Primary Hyperoxaluria - Pipeline ... Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) ... condition characterized by recurrent kidney and bladder stones. ... called oxalate. Symptoms include blood in the urine, ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... offering. ... global oxygen therapy devices market to grow at a CAGR of ... Oxygen Therapy Devices Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
Breaking Medicine Technology: